—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Laboratorios Farmaceuticos ROVI (ROVI.MC) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ROVI.MC, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in Europe: −1.2% week · −3.2% month · −6.1% quarter · +2.3% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Drug Manufacturers - Specialty & Generic · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against ROVI.MC on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Laboratorios Farmaceuticos ROVI

ROVI.MC in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Rovi makes and sells pharmaceutical products across Spain, the EU and other OECD markets, spanning prescription medicines, hospital products such as contrast agents and catheter-care lines, and contract-manufacturing services for injectable drugs including prefilled syringes and vials. It also develops its own molecules, including a low-molecular-weight heparin and newer central-nervous-system treatments. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain, operating as a subsidiary of Norbel Inversiones.
Where it sits in the stack
Rovi carries no seat in our index and sits outside the AI build-out stack; it belongs to the Healthcare sector of our wider universe, where it is tracked as a Spanish specialty and generic drugmaker rather than as part of any compute layer.
Who it is priced against
The diary has no defined peer group for Rovi; the market sometimes compares it with other European specialty and generic drugmakers, such as Grifols, given the shared Spanish base and hospital-product exposure.
Why Closelooknet tracks it
Rovi holds no index seat and no Closelooknet score; it does not feature in our editions, and the diary's only current record is its chart reading, tracked as background data rather than a scored constituent.
What the diary watches
Whether the contract-manufacturing side, which ties Rovi to injectable-drug demand from other pharmaceutical companies, shows any shift in order volume that would change how the diary reads its chart pattern.

Laboratorios Farmaceuticos ROVI (ROVI.MC) trades on the MC exchange in Spain, classified under Healthcare.

The Closelooknet company score reads 61/100 composite (momentum 25, quality 78, valuation 52) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 1.65%, annual · buybacks 55 m EUR in FY2025

Dividends and capital return

What ROVI.MC pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.96 EUR per share · a 1.65% yield on the 2026-10-06 close 1 distribution, paid once a year 2026-10-06
  • Change on the year +2.6% against the prior twelve months prior twelve months 0.94 EUR per share
  • Last distribution 0.96 EUR per share as the price series records it, within days of the ex-date 2026-07-13
  • By calendar year 2025: 0.94 EUR (partial) · 2026: 0.96 EUR to date first distribution recorded in the three-year window: 2025-07-14
  • Dividends paid, FY2025 48 m EUR 27% of earnings
  • Buybacks, FY2025 55 m EUR 1.9% of today's market value
  • Share count −0.2% in FY2025
  • Capital returned 103 m EUR · 85% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Laboratorios Farmaceuticos ROVI (ROVI.MC)?

Laboratorios Farmaceuticos ROVI trades as ROVI.MC on the MC exchange (Spain) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is ROVI.MC in a Closelooknet index?

Not currently — Laboratorios Farmaceuticos ROVI is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What is Laboratorios Farmaceuticos ROVI's Closelooknet composite score?

61 out of 100, with momentum 25, quality 78 and valuation 52 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ROVI.MC trade against its moving averages?

Downtrend stack: Trades -1.2% vs the 50-day and -11.8% vs the 200-day average, 31.8% below the 52-week high and +10% off the 52-week low; a death cross printed 77 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Laboratorios Farmaceuticos ROVI compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic), Laboratorios Farmaceuticos ROVI (ROVI.MC) sits 31.8% below its 52-week high, 1.2% below its 50-day average; Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is 4.2% below, Almirall S.A. (ALM.MC) is 26.2% below, Fagron NV (FAGR.BR) is 8.9% below. Put any of them next to ROVI.MC in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Laboratorios Farmaceuticos ROVI do?

Rovi makes and sells pharmaceutical products across Spain, the EU and other OECD markets, spanning prescription medicines, hospital products such as contrast agents and catheter-care lines, and contract-manufacturing services for injectable drugs including prefilled syringes and vials. It also develops its own molecules, including a low-molecular-weight heparin and newer central-nervous-system treatments. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain, operating as a subsidiary of Norbel Inversiones. The diary has no defined peer group for Rovi; the market sometimes compares it with other European specialty and generic drugmakers, such as Grifols, given the shared Spanish base and hospital-product exposure.

Where does Laboratorios Farmaceuticos ROVI sit in the AI build-out?

Rovi carries no seat in our index and sits outside the AI build-out stack; it belongs to the Healthcare sector of our wider universe, where it is tracked as a Spanish specialty and generic drugmaker rather than as part of any compute layer. Rovi holds no index seat and no Closelooknet score; it does not feature in our editions, and the diary's only current record is its chart reading, tracked as background data rather than a scored constituent.

Does Laboratorios Farmaceuticos ROVI pay a dividend?

Laboratorios Farmaceuticos ROVI has paid 0.96 EUR per share over the last twelve months, paid once a year, a trailing yield of 1.65% on the 2026-10-06 close; the last distribution recorded in the price series was 0.96 EUR on 2026-07-13. In fiscal 2025 the company paid 48 m EUR in dividends and bought back 55 m EUR of its own shares, 85% of that year’s free cash flow. The share count fell 0.2% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ROVI.MC, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.